Unitaid

Name

Unitaid

Legal name

Unitaid

Website

https://unitaid.org

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Global Health Financing and Market Shaping

NAICS

Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)

SIC

Services-Social Services (8300)

akta.pro primary industry

Global Health Financing Mechanisms (HLAJAKAC)

akta.pro secondary industries

Multilateral Global Health Agencies (UN/IFIs) (HLAJAKAA), Global Health Supply Chain & Procurement Organizations (HLAJAKAL), Disease-Specific Global Programs (HIV/TB/Malaria/NTDs) (HLAJAKAF), Global Health Financing Mechanisms & Pooled Funds (HLAJAOAC), Health Supply Chain, Procurement & Access to Medicines (BPADAIAI)

Keywords

• Global health financing
• Health product access
• Market shaping investments
• Innovative health partnerships
• Public health grants

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Grants and Donations: Unitaid receives financial investments from governments (Brazil, Canada, Chile, France, Japan, Norway, Portugal, Republic of Korea, Spain, United Kingdom), the European Union, Gates Foundation, Wellcome, and WHO Foundation. Founded in 2006 by Brazil, Chile, France, Norway and the United Kingdom.
2. Innovative Financing: Uses innovative financing solutions like volume guarantees to lower prices for health products and help get them to market. Building on legacy of successful innovative health financing including air levy mechanisms.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Unitaid finances and accelerates the development, introduction, and scale-up of innovative health products for HIV, tuberculosis, malaria, women's and children's health, and pandemic preparedness in low- and middle-income countries. It does this primarily through grants to implementing partners and market-shaping agreements (volume guarantees, ceiling prices, and technology partnerships) that drive down product costs and accelerate access for the people who need them most.

Product overview

Unitaid does not offer a single unified product but rather a portfolio of health product investments and initiatives across multiple disease areas. The organization works to accelerate access to innovative health products including: HIV prevention tools (lenacapavir twice-yearly injection), AI-powered diagnostic solutions (miLab CER for cervical cancer, AirRay 20 for TB screening), advanced HIV disease diagnostics (VITA CD4 Test), and novel testing approaches (pooled TB testing). Unitaid also supports regional manufacturing initiatives (MADE, MedSuRe Africa) to strengthen Africa's health product supply chains.

Differentiator

Problem solved

Functional benefit

Products and services

• MADE Program (Market Access and Diagnostic Equity) Unitaid-funded program that supports African manufacturers in developing and scaling diagnostic test production for regional and global markets, addressing the 70% of pharmaceuticals consumed in Africa that are imported.
• MedSuRe Africa Program Unitaid-funded program led by US Pharmacopeia (USP) that boosts regional production of essential medicines (including HIV, malaria, and postpartum hemorrhage treatments) and related quality testing infrastructure in Africa.
• Antimalarial Drug Resistance Initiative A US$26.5 million Unitaid-funded initiative led with Jhpiego to curb rising antimalarial drug resistance in Africa.
• Cervical Cancer Elimination Call for Proposals (Secondary Prevention) Unitaid funding call worth up to US$50 million for projects accelerating cervical cancer elimination through secondary prevention (screening and pre-cancer treatment) in low- and middle-income countries.
• Climate-Proof Health Products Funding Opportunity A US$10 million Unitaid funding opportunity to generate evidence on how extreme heat and humidity affect the safety, quality and effectiveness of essential medicines and health products in LMICs.
• Pregnant Women's Care Expansion Initiative A US$52 million Unitaid investment to expand lifesaving care for pregnant women in Africa.

Quantifiable outcome

• 390 million people benefit annually from Unitaid-supported health products
• +5 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Partnerships

18 partnerships are on record, tiered core, supporting and flagship.

• Elton John AIDS FoundationcoreStrategic or Co-development Partner · 13 May 2026Unitaid and Elton John AIDS Foundation advocating for urgent scale-up of lenacapavir for adolescent girls and young women in sub-Saharan Africa. Organizations secured ceiling price of approximately £30 per person per year for quality-assured generic versions.
• Clinton Health Access Initiative (CHAI)coreStrategic or Co-development Partner · 12 March 2026Unitaid, CHAI, and Wits RHI coordinated with Dr. Reddy's Laboratories to supply generic lenacapavir at $40 per person annually for 120 LMICs. Proof that early market-shaping can make affordability keep pace with innovation.
• Wits RHIcoreStrategic or Co-development Partner · 12 March 2026Wits RHI collaborated with Unitaid and CHAI to coordinate lenacapavir generic pricing agreement with Dr. Reddy's Laboratories for 120 low- and middle-income countries.
• FiocruzcoreStrategic or Co-development Partner · 5 March 2026South Africa negotiating voluntary license agreement with Gilead Sciences with support from Unitaid and US Pharmacopeia. Lenacapavir use kicked off in South Africa and Brazil through Unitaid partnership with Wits RHI and Fiocruz.
• FINDcoreImplementation/ SI/ Consulting Partner · 26 February 2026Unitaid invested US$44 million since 2022 to advance TB diagnostics through partnerships with LSTM and FIND. Multi-country trial demonstrated pooled testing reducing TB testing costs by up to 65%.
• Liverpool School of Tropical Medicine (LSTM)coreImplementation/ SI/ Consulting Partner · 26 February 2026Unitaid partnership with LSTM supporting TB diagnostics advancement as part of US$44 million investment since 2022.
• Noul Co. LtdsupportingStrategic or Co-development Partner · 6 January 2026Noul debuted AI-powered cervical cancer diagnostic solution miLab CER at CES 2026. Unitaid recommended miLab CER for use in 2024 alongside solutions from Roche and Hologic.
• Accesso BiotechsupportingStrategic or Co-development Partner · 18 December 2025Support from Gates Foundation, Unitaid, and CHAI to expand manufacturing and global access to VITA CD4 test for managing advanced HIV disease. Initiative aims to accelerate regulatory approval and scale production.
• Dr. Reddy's LaboratoriescoreStrategic or Co-development Partner · 22 November 2025Indian pharmaceutical company plan to produce generic versions of lenacapavir for $40 a year starting in 2027. Supported by Unitaid, Clinton Health Access Initiative, and Wits RHI to expand competitive generics ecosystem for the drug.
• Hetero LabscoreStrategic or Co-development Partner · 24 September 2025Gates Foundation partnership with Indian manufacturer Hetero Labs to produce low-cost generic version of lenacapavir at roughly $40 per patient per year, pending regulatory approval expected as early as 2027. Part of broader effort to accelerate affordable access to lenacapavir in LMICs.
• PATHflagshipImplementation/ SI/ Consulting Partner · 21 August 2025PATH leads MADE program receiving US$ 11 million to support African companies in developing and scaling diagnostic test production for regional and global markets. Part of US$ 50 million flagship programs to strengthen Africa's regional manufacturing.
• US Pharmacopeia (USP)flagshipImplementation/ SI/ Consulting Partner · 21 August 2025USP leads MedSuRe Africa program receiving US$ 35.5 million to boost production of essential medicines including HIV, malaria, and postpartum hemorrhage treatments along with related quality testing infrastructure.
• Medicines Patent PoolsupportingStrategic or Co-development Partner · 21 August 2025Medicines Patent Pool receives US$ 1.5 million for complementary work supporting the MedSuRe Africa flagship program for regional manufacturing.
• JhpiegocoreImplementation/ SI/ Consulting Partner · 21 August 2025Unitaid and Jhpiego launch US$26.5 million initiative to curb rising antimalarial drug resistance in Africa.
• PoskomcoreStrategic or Co-development Partner · 20 May 2025Unitaid and CHAI announced new pricing agreement with South Korean company Poskom to dramatically lower cost of AirRay 20 ultraportable digital chest x-ray system, making it available at discounted price to 138 LMICs.
• Japan / NikkisosupportingStrategic or Co-development Partner · 1 January 2025Unitaid and Japan's Nikkiso partner with Kenya and Tanzania to build liquid medical oxygen facilities in East Africa through project with Japanese government committing funds.
• World Health Organization (WHO)coreStrategic or Co-development Partner · 1 January 2006Unitaid is a hosted partnership of WHO. Credibility and insight through WHO hosting. Operations administered in accordance with Unitaid's constitution and WHO rules. WHO uses evidence from Unitaid investments to create policy and guidance.
• The Global FundcoreChannel Partner/ Reseller/ Distributor · 1 January 2006Collaboration with Global Fund to take products and best practices to scale. Global Fund is a major scale-up partner for Unitaid-supported interventions.

Scale indicators17 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Gavi, the Vaccine Alliance: Multilateral public-private partnership accelerating vaccine access in LMICs through innovative financing, market shaping, and Gavi-Advanced Market Commitments. Same financing/partnership DNA as Unitaid but focused on immunization.
• Medicines for Malaria Venture (MMV): Public-private partnership developing and delivering malaria treatments. Shares Unitaid's grant-funded, market-shaping approach and operates within the same global health ecosystem with overlapping donor and partner networks.
• PATH: Leads Unitaid's $11M MADE program for African diagnostic manufacturing and is a longstanding implementing partner across Unitaid's investment portfolio. Overlapping mission of accelerating health innovation in LMICs.
• Drugs for Neglected Diseases initiative (DNDi): Not-for-profit R&D organization developing treatments for neglected diseases (sleeping sickness, leishmaniasis, Chagas disease, etc.) with funding from public and philanthropic donors. Closely mirrors Unitaid's grant-funded, partnership-driven model for access-oriented health R&D.
• Clinton Health Access Initiative (CHAI): Operates as Unitaid's direct implementation co-pilot on market-shaping deals (lenacapavir generic pricing for 120 LMICs, AirRay 20 X-ray pricing for 138 LMICs). Both organizations negotiate volume guarantees and pooled procurement across the same disease portfolio.
• FIND (Foundation for Innovative New Diagnostics): Strategic implementation partner for Unitaid's TB diagnostics portfolio ($44M joint investment since 2022) and pooled testing trials. Both organizations focus on introducing diagnostic innovations to LMIC public health systems.
• The Global Fund to Fight AIDS, Tuberculosis and Malaria: Multilateral financing mechanism for the same three diseases Unitaid targets (HIV, TB, malaria), serving as Unitaid's primary scale-up partner to take innovative health products to LMICs. Operates with similar donor-funded, partnership-based model.
• Medicines Patent Pool: Founded by Unitaid in 2010 and still receiving direct Unitaid funding ($1.5M for MedSuRe Africa). MPP negotiates voluntary licenses for HIV, TB, and hepatitis C medicines in LMICs — a core enabler of Unitaid's generic pricing strategy.
• TB Alliance: Non-profit product development partnership advancing faster, cheaper TB regimens, working closely with Unitaid as a co-funder and implementer of TB innovations in LMICs.

Others

• Wellcome Trust: Major philanthropic funder of global health R&D and a current Unitaid donor. While not a direct competitor, Wellcome shapes the same funding and policy ecosystem and increasingly co-invests on issues like pandemic preparedness and climate-health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/unitaid
• LinkedInlinkedin.com/company/unitaid

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unitaid